These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17567120)

  • 1. On sampling of fragment space.
    Makara GM
    J Med Chem; 2007 Jul; 50(14):3214-21. PubMed ID: 17567120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similarity searching and scaffold hopping in synthetically accessible combinatorial chemistry spaces.
    Boehm M; Wu TY; Claussen H; Lemmen C
    J Med Chem; 2008 Apr; 51(8):2468-80. PubMed ID: 18380426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-based lead discovery: leads by design.
    Carr RA; Congreve M; Murray CW; Rees DC
    Drug Discov Today; 2005 Jul; 10(14):987-92. PubMed ID: 16023057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometric techniques for label-free high-throughput screening in drug discovery.
    Roddy TP; Horvath CR; Stout SJ; Kenney KL; Ho PI; Zhang JH; Vickers C; Kaushik V; Hubbard B; Wang YK
    Anal Chem; 2007 Nov; 79(21):8207-13. PubMed ID: 17902631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-based lead discovery: screening and optimizing fragments for thermolysin inhibition.
    Englert L; Silber K; Steuber H; Brass S; Over B; Gerber HD; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2010 Jun; 5(6):930-40. PubMed ID: 20394106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Virtual fragment linking": an approach to identify potent binders from low affinity fragment hits.
    Crisman TJ; Bender A; Milik M; Jenkins JL; Scheiber J; Sukuru SC; Fejzo J; Hommel U; Davies JW; Glick M
    J Med Chem; 2008 Apr; 51(8):2481-91. PubMed ID: 18357974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR fragment screening: tackling protein-protein interaction targets.
    Schade M; Oschkinat H
    Curr Opin Drug Discov Devel; 2005 May; 8(3):365-73. PubMed ID: 15892252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors.
    Kowalchick JE; Leiting B; Pryor KD; Marsilio F; Wu JK; He H; Lyons KA; Eiermann GJ; Petrov A; Scapin G; Patel RA; Thornberry NA; Weber AE; Kim D
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5934-9. PubMed ID: 17827003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical aspects of NMR-based fragment screening.
    Lepre CA
    Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
    Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
    Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based lead discovery: a chemical update.
    Erlanson DA
    Curr Opin Biotechnol; 2006 Dec; 17(6):643-52. PubMed ID: 17084612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hit-directed nearest-neighbor searching.
    Shanmugasundaram V; Maggiora GM; Lajiness MS
    J Med Chem; 2005 Jan; 48(1):240-8. PubMed ID: 15634017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based drug design.
    Feyfant E; Cross JB; Paris K; Tsao DH
    Methods Mol Biol; 2011; 685():241-52. PubMed ID: 20981527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which aspects of HTS are empirically correlated with downstream success?
    Bender A; Bojanic D; Davies JW; Crisman TJ; Mikhailov D; Scheiber J; Jenkins JL; Deng Z; Hill WA; Popov M; Jacoby E; Glick M
    Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment based drug discovery: practical implementation based on ¹⁹F NMR spectroscopy.
    Jordan JB; Poppe L; Xia X; Cheng AC; Sun Y; Michelsen K; Eastwood H; Schnier PD; Nixey T; Zhong W
    J Med Chem; 2012 Jan; 55(2):678-87. PubMed ID: 22165820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Yeh TK; Chen X; Huang CY; Chang CN; Yeh KC; Hsieh SH; Chien CH; Chang YW; Huang CH; Huang YW; Huang CL; Wu SH; Wang MH; Lu CT; Chao YS; Jiaang WT
    Bioorg Med Chem; 2009 Mar; 17(6):2388-99. PubMed ID: 19261480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-based activity space: smaller is better.
    Hesterkamp T; Whittaker M
    Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.